MORRIS PLAINS, N.J., May 19, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that IBC Pharmaceuticals, Inc., a majority-owned subsidiary (IBC), has received notice that its patent application for “Methods and compositions for generating bioactive assemblies of increased complexity and uses,” will issue as U.S. patent no. 7,534,866 today.
